Survival benefits and disparities in radiation therapy for elderly patients with pancreatic ductal adenocarcinoma

被引:0
|
作者
Bi-Yang Cao [1 ,2 ]
Qian-Qian Wang [1 ]
Le-Tian Zhang [1 ,2 ]
Chen-Chen Wu [1 ,2 ]
Fang Tong [1 ]
Wei Yang [1 ]
Jing Wang [1 ]
机构
[1] Department of Radiation Oncology,First Medical Center of Chinese PLA General Hospital
[2] Medical School of Chinese PLA
关键词
D O I
暂无
中图分类号
R735.9 [胰腺肿瘤];
学科分类号
100214 ;
摘要
BACKGROUND Older patients represent a unique subgroup of the cancer patient population, for which the role of cancer therapy requires special consideration. However, the outcomes of radiation therapy(RT) in elderly patients with pancreatic ductal adenocarcinoma(PDAC) are not well-defined in the literature.AIM To explore the use and effectiveness of RT in the treatment of elderly patients with PDAC in clinical practice.METHODS Data from patients with PDAC aged ≥ 65 years between 2004 and 2018 were collected from the Surveillance, Epidemiology, and End Results database.Multivariate logistic regression analysis was performed to determine factors associated with RT administration. Overall survival(OS) and cancer-specific survival(CSS) were evaluated using the Kaplan–Meier method with the log-rank test.Univariate and multivariate analyses with the Cox proportional hazards model were used to identify prognostic factors for OS. Propensity score matching(PSM)was applied to balance the baseline characteristics between the RT and non-RT groups. Subgroup analyses were performed based on clinical characteristics.RESULTS A total of 12245 patients met the inclusion criteria, of whom 2551(20.8%) were treated with RT and 9694(79.2%) were not. The odds of receiving RT increased with younger age, diagnosis in an earlier period, primary site in the head, localized disease, greater tumor size, and receiving chemotherapy(all P < 0.05).Before PSM, the RT group had better outcomes than did the non-RT group [median OS, 14.0 vs 6.0mo; hazard ratio(HR) for OS: 0.862, 95% confidence interval(CI): 0.819–0.908, P < 0.001; and HR for CSS: 0.867, 95%CI: 0.823–0.914, P < 0.001]. After PSM, the survival benefit associated with RT remained comparable(median OS: 14.0 vs 11.0 mo; HR for OS: 0.818, 95%CI: 0.768–0.872, P < 0.001;and HR for CSS: 0.816, 95%CI: 0.765–0.871, P < 0.001). Subgroup analysis revealed that the survival benefits(OS and CSS) of RT were more significant in patients aged 65 to 80 years, in regional and distant stages, with no surgery, and receiving chemotherapy.CONCLUSION RT improved the outcome of elderly patients with PDAC, particularly those aged 65 to 80 years, in regional and distant stages, with no surgery, and who received chemotherapy. Further prospective studies are warranted to validate our results.
引用
收藏
页码:155 / 170
页数:16
相关论文
共 50 条
  • [31] Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma
    Marius Distler
    Felix Rückert
    Maximilian Hunger
    Stephan Kersting
    Christian Pilarsky
    Hans-Detlev Saeger
    Robert Grützmann
    BMC Surgery, 13
  • [32] rognostic Estimator of Survival for Patients with Localized and Extended Pancreatic Ductal Adenocarcinoma
    Gleason, Michael X.
    Mdzinarishvili, Tengiz
    Are, Chandrakanth
    Sasson, Aaron
    Sherman, Alexander
    Shats, Oleg
    Sherman, Simon
    CANCER INFORMATICS, 2013, 12 : 103 - 114
  • [33] Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent
    Mayo, Skye C.
    Nathan, Hari
    Cameron, John L.
    Olino, Kelly
    Edil, Barish H.
    Herman, Joseph M.
    Hirose, Kenzo
    Schulick, Richard D.
    Choti, Michael A.
    Wolfgang, Christopher L.
    Pawlik, Timothy M.
    CANCER, 2012, 118 (10) : 2674 - 2681
  • [34] Radical resection benefits patients suffering pancreatic ductal adenocarcinoma with liver oligometastases
    Kong, Qingyan
    Teng, Fei
    Li, Hang
    Chen, Zheyu
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2024, 106 (01) : 51 - 60
  • [35] The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy
    Taherian, Mehran
    Katz, Matthew H. G.
    Prakash, Laura R.
    Wei, Dongguang
    Tong, Yi Tat
    Lai, Zongshan
    Chatterjee, Deyali
    Wang, Hua
    Kim, Michael
    Tzeng, Ching-Wei D.
    Ikoma, Naruhiko
    Wolff, Robert A.
    Zhao, Dan
    Koay, Eugene J.
    Maitra, Anirban
    Wang, Huamin
    CANCERS, 2024, 16 (19)
  • [36] Survival and Prognostic Factors in Patients With Pancreatic Colloid Carcinoma Compared With Pancreatic Ductal Adenocarcinoma
    Khalil, Lana
    Huang, Zhonglu
    Zakka, Katerina
    Jiang, Renjian
    Penley, McKenna
    Alese, Olatunji B.
    Shaib, Walid L.
    Wu, Christina
    Behera, Madhusmita
    Reid, Michelle D.
    El-Rayes, Bassel F.
    Akce, Mehmet
    PANCREAS, 2023, 52 (01) : E75 - E84
  • [37] Effect of chemotherapy on survival of patients with recurrent pancreatic ductal adenocarcinoma (PDAC) following surgical therapy.
    Gbolahan, Olumide B.
    Tong, Yan
    O'Neil, Bert H.
    Shanda, Safi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation
    Estrella, Jeannelyn S.
    Rashid, Asif
    Fleming, Jason B.
    Katz, Matthew H.
    Lee, Jeffrey E.
    Wolf, Robert A.
    Varadhachary, Gauri R.
    Pisters, Peter W. T.
    Abdalla, Eddie K.
    Vauthey, Jean-Nicolas
    Wang, Hua
    Gomez, Henry F.
    Evans, Douglas B.
    Abbruzzese, James L.
    Wang, Huamin
    CANCER, 2012, 118 (01) : 268 - 277
  • [39] Outcomes of Margin Status on Survival in Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Therapy
    Swami, Ashish
    Varshney, Vaibhav Kumar
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2021, 232 (06) : 1022 - 1023
  • [40] Impact of Radiation Therapy Sequence on Survival Among Patients With Resected Pancreatic Head Ductal Carcinoma
    Franko, Jan
    Puri, Dev R.
    Goldman, Charles D.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (01) : 26 - 30